Skip to main content

Ionis Pharmaceuticals Inc

IONS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0000874015

In the last 90 days, Ionis Pharmaceuticals Inc insiders filed 1 open-market purchase and 2 sales; 464 institutions reported holding it in 13F filings for Q3 2026, worth $7.66B in total; ARK Invest is the only superinvestor holding it.

Key figures

Market capClose on Nov 19, 2026
$4.53B
Insider buysLast 90 days, $148.2K in total
1
Insider sellsLast 90 days, $61.4K in total
2
13F holdersQ3 2026, −45 vs. previous quarter
464
13F valueReported value at the end of Q3 2026
$7.66B
Superinvestors holdingAt the end of Q3 2026
1

Price chart

From SEC filings, in USD.

Revenue, FY2025
$943.7M
+33.8% year over year
Net income, FY2025
-$381.4M
No comparable prior period
Free cash flow, FY2025
-$320.0M
No comparable prior period
Revenue, Q3 FY2026
$242.7M
+54.9% year over year

Revenue flow, FY2025

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Net loss for FY2025: $381.4M (40.4% of revenue).

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
21.2M
Shares sold short
Change
+512.8K
+2.5% vs. previous
Days to cover
8.41
At average daily volume

Superinvestors holding IONS, Q3 2026

Go to the superinvestors tab

1 superinvestor reports holding Ionis Pharmaceuticals Inc on Form 13F. Percentages are the stock's share of each portfolio.

ARK Invest

Cathie Wood

0.2%

Ionis Pharmaceuticals Inc's share of the portfolio

Shares
923,162
Value
$41.2M

Latest insider trades

See all insider trades

Open-market purchases and sales by Ionis Pharmaceuticals Inc insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Nov 13, 2026 (view filing)4:19 PM ETNov 103 daysHayden Michael RDirectorPPurchase+5.00K$29.64+$148.2K+22.7%27.0K after
Oct 19, 2026 (view filing)9:40 PM ETOct 163 daysDevers Shannon L.EVP, Chief Human Resources OfcSSale−1.36K$43.54−$59.1K−7.1%17.8K after
Oct 19, 2026 (view filing)9:40 PM ETOct 163 daysSwayze EricEVP ResearchSSale−53$43.54−$2.31K−12.0%390 after
Jul 31, 2026 (view filing)4:42 PM ETJul 30-311 dayHayden Michael RDirectorPPurchase+20.0K$52.94+$1.06M+500.0%24.0K after2 lots
Jul 9, 2026 (view filing)7:26 PM ETJul 72 daysBennett C FrankEVP, Chief Scientific OfficerSSale−5.54K$83.58−$462.7K−6.9%75.0K after10b5-1
Jul 9, 2026 (view filing)7:26 PM ETJul 72 daysBennett C FrankEVP, Chief Scientific OfficerSSale−15.0K$85.46−$1.28M−100.0%0 after10b5-1
Jul 9, 2026 (view filing)6:07 PM ETJul 72 daysDiaz Allene M.DirectorSSale−10.1K$85.42−$863.6K−72.6%3.81K after10b5-1
Jul 9, 2026 (view filing)6:07 PM ETJul 72 daysKordasiewicz Holly B.EVP, Chief Development OfficerSSale−362$84.30−$30.5K−1.6%22.1K after10b5-1
Jul 6, 2026 (view filing)6:49 PM ETJul 15 daysKlein Joseph IIIDirectorSSale−11.5K$79.04−$910.4K−51.1%11.0K after2 lots10b5-1
Jun 30, 2026 (view filing)Jun 264 daysBaroldi JosephEVP, Chief Business OfficerSSale−5.63K$80.16−$451.7K−54.7%4.67K after10b5-1

Top 10 13F holders, Q3 2026

See all 464 holders

The largest institutional positions in Ionis Pharmaceuticals Inc at the end of Q3 2026; share changes are against Q2 2026.

Institutions holding IONS in Q3 2026
InstitutionSharesValue% of portfolioChange in sharesAction
FMR LLC24,740,108$1.10B0.05%+108,152+0.4%Added
Capital World Investors21,787,273$972.8M0.12%+118,047+0.5%Added
BlackRock, Inc.13,192,834$589.1M0.01%+2,488,174+23.2%Added
Vanguard Portfolio Management LLC7,719,464$344.7M0.02%−140,065−1.8%Reduced
Vanguard Capital Management LLC7,218,530$322.3M0.01%+7,033+0.1%Added
Two Sigma Investments, LP6,727,410$300.4M0.22%+475,068+7.6%Added
State Street Corp5,710,900$255.0M0.01%+1,376,052+31.7%Added
Citadel Advisors LLC4,026,275$179.8M0.10%+3,789,991+1,604.0%Added
Wellington Management Group LLP3,430,545$153.2M0.03%−4,220,870−55.2%Reduced
Geode Capital Management, LLC3,277,569$146.4M0.01%−306,455−8.6%Reduced

Holders of 5% or more of IONS

See all 3 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Ionis Pharmaceuticals Inc.

Largest holders of IONS from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
Capital World Investors13G/A12.80%21.2M shares+1.70 ppfrom 11.10%Feb 13, 20253 filingsMay 14, 2026SEC
BlackRock, Inc.13G/A5.70%9.07M shares–Apr 17, 20251 filingApr 17, 2025SEC
Vanguard Capital Management LLC13G5.05%8.34M sharesNewApr 30, 20261 filingApr 30, 2026SEC

2 members of Congress reported 3 trades in Ionis Pharmaceuticals Inc since 2020. Newest filings:

  1. Daniel S. Goldman

    House · NY · Apr 17, 2023

    Sell$1K-$15K

  2. Donna E. Shalala

    House · FL · Apr 27, 2020

    Sell$1K-$15K

  3. Donna E. Shalala

    House · FL · Apr 27, 2020

    Buy$1K-$15K